北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688181 证券简称：八亿时空 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 11 月 1 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议资料 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议资料目录 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议须知......3 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议议程......5 议案一：《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》... 7 议案二：《关于修订、废止及制定公司部分治理制度的议案》............................8 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议须知 各位股东及股东代表： 为维护股东的合法权益，确保股东及股东代表在北京八亿时空液晶科技股份 有限公司（以下简称"公司"）2025 年第二次临时股东大会期间依法行使权利， 保证股东大会的正常秩序和议事效率，依据 ...

Core Viewpoint - The company, Beijing Eight Billion Space Liquid Crystal Technology Co., Ltd., has initiated a share repurchase program to enhance shareholder value and potentially support employee stock ownership plans [1][2]. Summary by Sections 1. Basic Information on Share Repurchase - On May 16, 2025, the company’s board approved a share repurchase plan using its own funds and a special loan of up to 70 million RMB from Shanghai Pudong Development Bank [1] - The repurchase will target a maximum price of 40 RMB per share, with a total repurchase amount between 50 million RMB and 100 million RMB [1] - The repurchase period is set for 12 months from the board's approval date [1] 2. Progress of Share Repurchase - As of October 31, 2025, the company has repurchased a total of 477,000 shares, representing 0.35% of its total share capital of 134,481,546 shares [2] - The highest price paid for the repurchased shares was 28.20 RMB, while the lowest was 27.69 RMB, with a total expenditure of approximately 13.37 million RMB (excluding transaction fees) [2] - The repurchase activities are in compliance with relevant laws and the company's repurchase plan [2] 3. Other Matters - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [3]

Core Viewpoint - On November 3, the company announced that it did not conduct any share buybacks in October 2025 [2] Company Summary - The company, 八亿时空, released an announcement regarding its share buyback activities [2]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]

北京八亿时空液晶科技股份有限公司 证券代码：688181 证券简称：八亿时空 公告编号：2025-044 本次回购股份符合相关法律法规及公司回购股份方案的规定。 三、其他事项 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/5/17 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 16 5 | 5 | 日~2026 | 年 | 月 | 15 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 477,000股 | | | | | | | 累计已回购股数占总股本比例 | 0.35% | | | | ...

Summary of Conference Call for Company and Industry Analysis Company Overview - **Company**: 八亿时空 (Eight Billion Space) - **Industry**: Semiconductor materials, LCD materials, OLED materials, pharmaceuticals, and pesticides Key Points and Arguments Production and Revenue Projections - The company has maximized production capacity and economic value at the 上虞基地 (Shangyu Base) through programmatic, standardized, and intelligent processes, achieving ton-level mass production delivery in July 2023. Expected revenue for 2025 is over 20 million yuan [2][3] - 南通占鼎材料 (Nantong Zhangding Materials) is preparing for the second phase of production at its Gansu factory, expected to start next month, adding over 100 tons of fluorinated liquid capacity monthly. Current monthly shipment from the first phase is about 10 tons [2][5] Market Demand and Clientele - The company holds orders worth approximately 500 million yuan, with significant demand for fluorinated liquids, indicating that even with the second phase's output, market demand will not be fully met [2][7] - Major clients include Samsung and Hynix, indicating strong ties with leading semiconductor manufacturers [2][5] LCD Business Insights - The LCD segment remains a stable cash flow source, although growth potential for display LCDs is limited. Non-display LCDs, such as adjustable glass for vehicles, show promising demand, potentially becoming a future growth point [2][9] - Domestic companies are rising, impacting the market share of overseas firms, thus providing opportunities for domestic market share growth [2][9] OLED Materials Strategy - The company focuses on front-end materials in the OLED sector, leveraging its advantages in monomer synthesis and production capacity at the Shangyu Base. The company is selective in order acceptance to maintain gross margins amid fierce domestic competition [2][9][11] - Despite a challenging overseas market for OLED materials, there is significant growth potential in the domestic market, with a year-on-year revenue increase of approximately 30% in Q3 [10][11] Pharmaceutical and Pesticide Segments - The pharmaceutical segment focuses on innovative and generic drug intermediates, adjusting product selection strategies due to industry adjustments and oversupply. Expected revenue for this segment is several million yuan this year, potentially exceeding 100 million yuan next year [4][13][14] - The pesticide segment benefits from green channel qualifications, contributing to revenue growth [4][13] Semiconductor Materials - In the semiconductor photoresist sector, the company is a domestic leader, collaborating with top firms to provide customized services. Plans include consolidating the domestic market before expanding internationally [4][15] Strategic Product Development - The company emphasizes strategic selection in its knife belt products, aiming to enhance competitiveness through optimized supply chains. Expected contributions from this segment could reach tens of millions in revenue [4][12] - The PSPI business faces intense competition, prompting the company to explore differentiated survival strategies, particularly in the non-fluorinated PSPI field [4][16] Supply Chain and Production Integration - The Shangyu Base will facilitate integrated production of LCD raw materials, with a focus on in-house production of certain materials to leverage proprietary technology and processes [4][17][18] Financial Reporting and Earnings - The company does not consolidate earnings from its investment in 詹宁 (Zhanning) as it is not a controlling entity, thus these projects are accounted for as investments rather than revenue [4][19] This summary encapsulates the key developments and strategic directions of 八亿时空 and its associated industries, highlighting growth opportunities, market dynamics, and production capabilities.

Group 1 - The core point of the news is that Ba Yi Shi Kong (688181.SH) reported its Q3 2025 results, revealing a decline in institutional investor holdings by 8.86 percentage points compared to the previous quarter, with a total of 485.79 thousand shares held by five institutional investors, representing 3.61% of the total share capital [1] - Among public funds, only one fund, Dongfang Quantitative Growth Flexible Allocation Mixed A, increased its holdings, while 74 public funds, including Huatai-PB Technology Innovation Mixed A and Bosera Shanghai Stock Exchange Science and Technology Innovation Board New Materials ETF, were not disclosed in the current period [1] - For social security funds, one fund, Huatai-PB Fund Management Co., Ltd. - Social Security Fund 17022 Portfolio, reduced its holdings by 1.47%, while another fund, Huatai-PB Fund Management Co., Ltd. - Social Security Fund 423 Portfolio, was not disclosed in the current period [2]

Core Insights - The company reported a steady recovery in its performance, with Q3 2025 revenue reaching 230 million yuan, a year-on-year increase of 32.73% and a quarter-on-quarter increase of 14.14%, while net profit attributable to shareholders was 14.6964 million yuan, up 23.32% year-on-year and 115.20% quarter-on-quarter [1] Group 1: Industry Developments - The Chinese government has emphasized the acceleration of domestic semiconductor material production, providing a historic opportunity for the development of photoresist resin [2] - The photoresist industry has faced long-standing challenges due to the monopoly of Japanese and American companies on key raw materials, which has hindered domestic production [2] - The company has established a dedicated R&D team for photoresist resin, achieving international advanced levels in key indicators for KrF photoresist resin [2] Group 2: Production Capacity and Technology - The company has successfully launched the first domestic high-automation flexible/volume production dual production line for KrF photoresist resin, which has entered mass production [3] - The overall design capacity of the two production lines is at the hundred-ton level, utilizing the company's self-developed automation control system to enhance production efficiency and reduce operational errors [3] - Future plans include gradually expanding production capacity to achieve an annual output of 200-300 tons of high-end photoresist resin within the next two to three years [3] Group 3: Business Strategy and Growth - The company is diversifying its growth strategy by leveraging its core display materials business while accelerating its entry into the semiconductor materials sector [4] - The liquid crystal materials business continues to perform steadily, with successful mass production of high-performance materials for various applications [4] - The company has made significant progress in OLED materials, optimizing production processes and establishing partnerships with domestic and international OLED material companies [4] Group 4: Breakthroughs in Polyimide - The company has achieved breakthroughs in both display and packaging dimensions within the polyimide sector, with successful testing and validation of various products [5] - The company is advancing in the area of advanced packaging PSPI, completing small-scale tests and preparing for customer validation [5] Group 5: Future Outlook - The company is positioned to leverage breakthroughs in domestic photoresist resin production to drive growth in two high-demand sectors, enhancing its capabilities for independent control of high-end materials [6] - Continuous expansion of production capacity and customer validation efforts are expected to strengthen the company's position in the industry [6]

Core Insights - The company reported a total operating revenue of 645 million yuan for the first three quarters of 2025, representing a year-on-year increase of 17.6% [1] - The net profit attributable to shareholders decreased to 45.57 million yuan, reflecting a year-on-year decline of 26.06% [1] - The basic earnings per share stood at 0.35 yuan [1]

证券代码：688181 证券简称：八亿时空 公告编号：2025-042 二、公司章程修订情况 为进一步提升公司的规范运作水平，根据《公司法》《关于新<公司法>配套 制度规则实施相关过渡期安排》《上市公司章程指引（2025 年修订）》《上海 证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等有关规定，结合公司实际情况，公司拟对《公司章程》 中的部分条款进行修订，具体内容如下： | 修订前 | 修订后 | | --- | --- | | 第一条 为维护北京八亿时空液晶 | 第一条 为维护北京八亿时空液晶 | | 科技股份有限公司（以下简称"公司"）、 | 科技股份有限公司（以下简称"公司"）、 | | 股东和债权人的合法权益，规范公司的组 | 股东、职工和债权人的合法权益，规范公 | | 织和行为，根据《中华人民共和国公司法》 | 司的组织和行为，根据《中华人民共和国 | | （以下简称"《公司法》"）、《中华人 | 公司法》（以下简称《公司法》）、《中 | | 民共和国证券法》（以下简称"《证券 | 华人民共和国证券法》（以下简称《证券 | | 法》"）、《上市 ...